Delivery Order SPE2DR25D3301-SPE2DR26F19RU
Award Date 12/17/25
Potential Completion Date 1/9/26
Potential Value $9K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $8,504.62 delivery order to AmerisourceBergen Drug Corp on April 24, 2025, for the supply of Tecentriq (atezolizumab) 840 mg/14 mL vials. This competitively awarded, firm fixed-price contract is scheduled for completion by May 15, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award carries no set-aside designation, reflecting the vendor's capability to compete successfully in open procurement processes for federal...
- The Defense Logistics Agency awarded a $17,009.24 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of Tecentriq (atezolizumab) 840 mg/14 mL vials on May 19, 2025, with completion targeted for June 10, 2025. This non-set-aside award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, which carries a $999,999,999 ceiling and runs through December 2026. The pharmaceutical distributor is...
- The Defense Logistics Agency awarded a delivery order valued at $8,962.54 to AmerisourceBergen Drug Corp for Tecentriq 840 mg/14 mL vials on December 16, 2025. This competitively awarded, firm fixed-price contract is scheduled for completion by January 8, 2026, with performance at the contractor's corporate office location in Conshohocken, Pennsylvania. Tecentriq is a specialized oncology medication used in cancer treatment protocols, reflecting the Defense Logistics Agency's role in supplying...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on November 28, 2025, for the supply of Tecentriq (atezolizumab) 840 mg/14 mL vials. The contract, valued at $8,962.54, is a firm fixed-price delivery order with an ultimate completion date of December 19, 2025. This award represents a non-competitive, competitively awarded delivery order executed through AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a $8,504.62 delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Tecentriq (atezolizumab) 840 mg/14 ml vials. This is a firm fixed price, non-set-aside contract with an ultimate completion date of October 14, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with...
- The Defense Logistics Agency's Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $34,018.40 on September 22, 2025, for the supply of Tecentriq 840 mg/14 ml vials. This is a firm fixed price, non-set-aside contract with an ultimate completion date of October 14, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tecentriq is a specialized oncology pharmaceutical product, reflecting the company's role as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 8, 2025, for the supply of Tecentriq (atezolizumab) 840 mg/14 mL vials, a monoclonal antibody cancer immunotherapy medication. This firm fixed-price delivery order, valued at $17,925.08, is a non-competitive set-aside award and is scheduled for completion by December 30, 2025. The pharmaceutical will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Tecentriq 840 mg/14 ml vials. This $4,252.30 delivery order, which carries a firm fixed price contract type with no set-aside designation, is scheduled for completion by November 12, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. Tecentriq is a specialized pharmaceutical product used in oncology treatment, reflecting the critical role...
- The Defense Logistics Agency awarded a $17,009.24 delivery order to AmerisourceBergen Drug Corp for Tecentriq 840 mg/14 ml vials on July 21, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order carries no set-aside designation, indicating it was competitively awarded. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, the company's corporate headquarters and a major distribution hub for federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $8,504.62 on September 19, 2025, for the supply of Tecentriq 840 mg/14 ml vials. This is a firm fixed-price delivery order with an ultimate completion date of October 10, 2025, with performance to be executed at the vendor's facility in Conshohocken, Pennsylvania. The contract represents a non-set-aside award made through open competition, reflecting AmerisourceBergen's demonstrated capability to fulfill...